179 related articles for article (PubMed ID: 37769157)
1. Considerations and Approaches for Cancer Immunotherapy in the Aging Host.
Ontiveros CO; Murray CE; Crossland G; Curiel TJ
Cancer Immunol Res; 2023 Nov; 11(11):1449-1461. PubMed ID: 37769157
[TBL] [Abstract][Full Text] [Related]
2. Considerations for successful cancer immunotherapy in aged hosts.
Hurez V; Padrón ÁS; Svatek RS; Curiel TJ
Clin Exp Immunol; 2017 Jan; 187(1):53-63. PubMed ID: 27690272
[TBL] [Abstract][Full Text] [Related]
3. Considerations for successful cancer immunotherapy in aged hosts.
Hurez V; Padrón Á; Svatek RS; Curiel TJ
Exp Gerontol; 2018 Jul; 107():27-36. PubMed ID: 28987644
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of immune evasion in breast cancer.
Bates JP; Derakhshandeh R; Jones L; Webb TJ
BMC Cancer; 2018 May; 18(1):556. PubMed ID: 29751789
[TBL] [Abstract][Full Text] [Related]
5. Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.
Spranger S; Sivan A; Corrales L; Gajewski TF
Adv Immunol; 2016; 130():75-93. PubMed ID: 26923000
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy: Reshape the Tumor Immune Microenvironment.
Lv B; Wang Y; Ma D; Cheng W; Liu J; Yong T; Chen H; Wang C
Front Immunol; 2022; 13():844142. PubMed ID: 35874717
[TBL] [Abstract][Full Text] [Related]
7. Advancing Immunotherapy in Metastatic Breast Cancer.
Mansour M; Teo ZL; Luen SJ; Loi S
Curr Treat Options Oncol; 2017 Jun; 18(6):35. PubMed ID: 28534250
[TBL] [Abstract][Full Text] [Related]
8. Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
Nixon AB; Schalper KA; Jacobs I; Potluri S; Wang IM; Fleener C
J Immunother Cancer; 2019 Nov; 7(1):325. PubMed ID: 31775882
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice.
Garcia MG; Deng Y; Murray C; Reyes RM; Padron A; Bai H; Kancharla A; Gupta H; Shen-Orr S; Curiel TJ
Aging Cancer; 2022 Mar; 3(1):68-83. PubMed ID: 36876140
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
Lazăr DC; Avram MF; Romoșan I; Cornianu M; Tăban S; Goldiș A
World J Gastroenterol; 2018 Aug; 24(32):3583-3616. PubMed ID: 30166856
[TBL] [Abstract][Full Text] [Related]
11. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
12. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
13. Optimization of immunotherapy in elderly cancer patients.
Tomihara K; Curiel TJ; Zhang B
Crit Rev Oncog; 2013; 18(6):573-83. PubMed ID: 24579736
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
15. PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy.
Conciatori F; Bazzichetto C; Falcone I; Ciuffreda L; Ferretti G; Vari S; Ferraresi V; Cognetti F; Milella M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32727102
[TBL] [Abstract][Full Text] [Related]
16. Current and Prospective Methods for Assessing Anti-Tumor Immunity in Colorectal Cancer.
Nussbaum YI; Manjunath Y; Suvilesh KN; Warren WC; Shyu CR; Kaifi JT; Ciorba MA; Mitchem JB
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946558
[TBL] [Abstract][Full Text] [Related]
17. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
Zheng W; Qian C; Tang Y; Yang C; Zhou Y; Shen P; Chen W; Yu S; Wei Z; Wang A; Lu Y; Zhao Y
Front Immunol; 2022; 13():1035323. PubMed ID: 36439137
[TBL] [Abstract][Full Text] [Related]
18. Platelet-Mediated Protection of Cancer Cells From Immune Surveillance - Possible Implications for Cancer Immunotherapy.
Schmied L; Höglund P; Meinke S
Front Immunol; 2021; 12():640578. PubMed ID: 33777033
[TBL] [Abstract][Full Text] [Related]
19. Nano-Immune-Engineering Approaches to Advance Cancer Immunotherapy: Lessons from Ultra-pH-Sensitive Nanoparticles.
Li S; Bennett ZT; Sumer BD; Gao J
Acc Chem Res; 2020 Nov; 53(11):2546-2557. PubMed ID: 33063517
[TBL] [Abstract][Full Text] [Related]
20. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
